



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Losatuxizumab

Cat. No.:	HY-P99715
CAS No.:	1801544-27-3
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC ₅₀ s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR ^{C271A,C283A} , 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers ^{[1][2]} .								
In Vitro	Losatuxizumab (0.001 nM-100 nM) binds to EGFRvIII-expressing cell line U87MGde2-7 ^[1] . Losatuxizumab inhibits EGF-mediated EGFR phosphorylation in a NR6 huEGFR ^{C271A,C283A} cell line, with an IC ₅₀ of 1.2 nM ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	<p>Lorigerlimab has antitumor activities in various wild-type EGFR-expressing squamous cell carcinoma xenograft model^[1]. Lorigerlimab (40 mg/kg, i.p.) significantly inhibits growth of U87MGde2-7 tumor in mice^[1].</p> <p>Lorigerlimab (10 and 40 mg/kg, i.p.) prolongs survival and reduces levels of pEGFR in PDX GBM model (SN0207 tumor)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>PDX GBM model (SN0207 tumor)^[1]</td></tr><tr><td>Dosage:</td><td>40 mg/kg</td></tr><tr><td>Administration:</td><td>i.p.</td></tr><tr><td>Result:</td><td>Prolonged survival rate, and reduced levels of pEGFR in tumor.</td></tr></table>	Animal Model:	PDX GBM model (SN0207 tumor) ^[1]	Dosage:	40 mg/kg	Administration:	i.p.	Result:	Prolonged survival rate, and reduced levels of pEGFR in tumor.
Animal Model:	PDX GBM model (SN0207 tumor) ^[1]								
Dosage:	40 mg/kg								
Administration:	i.p.								
Result:	Prolonged survival rate, and reduced levels of pEGFR in tumor.								

REFERENCES

[1]. Reilly EB, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.

[2]. Phillips AC, et al. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther. 2016 Apr;15(4):661-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA